- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03830151
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
Hyperpolarized Pyruvate Imaging of Glioma: Imaging-Pathological Correlation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To establish a clinical infrastructure for performing hyperpolarized carbon C 13 pyruvate (hyperpolarized 13-C-pyruvate) imaging in the human brain at MD Anderson.
SECONDARY OBJECTIVES:
I. To assess the correlation between conversion rate of hyperpolarized pyruvate to lactate (kpl) values and Ki-67 quantitation in the tumor.
II. To compare kpl values between tumor and normal brain within patient. III. To assess the association between kpl values and pathology results, including conventional, diffusion, perfusion, and permeability imaging.
IV. To assess the association between kpl values and magnetic resonance (MR) imaging findings.
V. To assess the association between kpl values and genomic findings, including methylation, ribonucleic acid [RNA], and deoxyribonucleic acid [DNA]).
OUTLINE:
Patients receive hyperpolarized carbon C 13 pyruvate intravenously (IV) over 10-20 seconds and then undergo an MRSI scan.
After completion of study, patients are followed up for 1 day.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Dawid Schellingerhout
- Phone Number: 713-794-5673
- Email: dawid.schellingerhout@mdanderson.org
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- M D Anderson Cancer Center
-
Contact:
- Dawid Schellingerhout
- Phone Number: 713-794-5673
-
Principal Investigator:
- Dawid Schellingerhout
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Written informed consent will be obtained from each participants including healthy volunteers.
- Healthy volunteers will not have contra-indications to MR scanning, but will otherwise not be subject to other selection criteria.
- All patients will be enrolled in study # 2011-0370, the Stereotactic RadPath trial
- Patient is >18 years old, agrees to participate in the clinical study and to complete all required visits and evaluations. The pediatric population has a different disease profile from the glioma patients we hope to recruit. To reduce heterogeneity in the patient population we will not consider patients younger than 18 for this study.
- Patient is a candidate for cerebral tumor resection with lesion suspected to be or previously biopsy proven to be a primary brain tumor.
- Patient is able to understand and give consent to participation in the study.
- Patient agrees to undergo, prior to the procedure, magnetic resonance imaging (MRI, within 14 days and preferably with 3 days of the planned procedure) with perfusion, diffusion and spectroscopic imaging.
- Patient has a GFR > 60. In patients with moderate renal failure (GFR 30-60), an alternate injection with 2 times half-dose multihance (gadobenate dimeglumine) or gadovist (gadobutrol) will be considered, if a contrast exam is deemed clinically necessary.
- Specifically for this Study: Patient is willing to give signed informed consent for C13-Pyruvate MR Spectroscopy.
Exclusion Criteria:
- Healthy volunteers will be screened using same process but will otherwise not be subject to other selection criteria.
- The patient is found to have unfavorable anatomy to indicate that stereotactic biopsy could not be safely performed.
- Pacemakers, electronic stimulation, metallic foreign bodies and devices and/or other conditions that are not MR safe, which include but are not limited to: • electronically, magnetically, and mechanically activated implants • ferromagnetic or electronically operated active devices like automatic cardioverter defibrillators and cardiac pacemakers • metallic splinters in the eye • ferromagnetic hemostatic clips in the central nervous system (CNS) or body • cochlear implants • other pacemakers, e.g., for the carotid sinus • insulin pumps and nerve stimulators • non-MR safe lead wires • prosthetic heart valves (if dehiscence is suspected) • non-ferromagnetic stapedial implants • pregnancy • claustrophobia that does not readily respond to oral medication
- Prior brain tumor treatment, including surgical resection, radiation therapy or chemotherapy for a primary brain neoplasm. Previous biopsy will not disqualify the patient from participation. Remote history (> 6month) of non-CNS malignancy in remission, without evidence of current/ prior brain metastasis, will also not disqualify patient from participating.
- History of cardiac arrhythmia
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Diagnostic (carbon C 13 pyruvate, MRSI)
Patients receive hyperpolarized carbon C 13 pyruvate IV over 10-20 seconds and then undergo an MRSI scan.
|
Undergo MRSI
Other Names:
Given IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Successful collection of hyperpolarized pyruvate magnetic resonance (MR) (HMR) imaging data
Time Frame: Up to 1 year
|
The kpl values will be calculated for each biopsy site, tumor border zone, and the contralateral side.
|
Up to 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ki-67 quantitation
Time Frame: Up to 1 year
|
Spearman's rank correlation will be used to assess the association between kpl values and Ki-67 if the samples are assumed to be independent.
Otherwise, intraclass correlation coefficient (ICC) of random effects models will be used.
|
Up to 1 year
|
Tumor kpl values
Time Frame: Up to 1 year
|
Will compare with normal brain kpl values.
Linear mixed models will be used.
|
Up to 1 year
|
Normal brain kpl values
Time Frame: Up to 1 year
|
Will compare with tumor kpl values.
Linear mixed models will be used.
|
Up to 1 year
|
Pathology results
Time Frame: Up to 1 year
|
Correlation with kpl values will be determined through generalized linear mixed models.
|
Up to 1 year
|
MR imaging findings
Time Frame: Up to 1 year
|
Correlation with kpl values will be determined through generalized linear mixed models.
|
Up to 1 year
|
Genomic findings
Time Frame: Up to 1 year
|
Correlation with kpl values will be determined through generalized linear mixed models.
|
Up to 1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Dawid Schellingerhout, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018-0902 (Other Identifier: M D Anderson Cancer Center)
- NCI-2019-00007 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Brain Neoplasm
-
M.D. Anderson Cancer CenterRecruitingMetastatic Malignant Neoplasm in the Brain | Central Nervous System Neoplasm | Leptomeningeal Neoplasm | Primary Brain NeoplasmUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedMetastatic Malignant Neoplasm in the Brain | Recurrent Brain Neoplasm | Primary Brain NeoplasmUnited States
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI); Oregon Health and Science UniversityTerminatedMetastatic Malignant Neoplasm in the Brain | Primary Brain NeoplasmUnited States
-
National Cancer Institute (NCI)TerminatedCentral Nervous System Neoplasms | Brain Cancer | Neoplasms, Brain | Primary Brain Neoplasms | Cancer of the BrainUnited States
-
M.D. Anderson Cancer CenterSanofi-SynthelaboCompletedUnknown Primary NeoplasmsUnited States
-
Royal Adelaide HospitalCompletedNeoplasm Metastasis | Brain NeoplasmAustralia
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Malignant Neoplasm in the Brain | Metastatic Malignant NeoplasmUnited States
-
National Cancer Institute (NCI)CompletedBrain Cancer | Brain Neoplasm | Brain Tumor, PrimaryUnited States
-
RenJi HospitalUnknownMultiple Primary NeoplasmChina
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)TerminatedMetastatic Malignant Neoplasm in the Brain | Metastatic Malignant Neoplasm | HLA-A2 Positive Cells PresentUnited States
Clinical Trials on Magnetic Resonance Spectroscopic Imaging
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
American College of Radiology Imaging NetworkNational Cancer Institute (NCI)Completed
-
Emory UniversityNational Cancer Institute (NCI)RecruitingMalignant Brain GliomaUnited States
-
Abramson Cancer Center of the University of PennsylvaniaCompletedBrain TumorUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnBrain and Central Nervous System Tumors
-
Susan ChangGE Healthcare; Sigma-Aldrich; Phillips-MedisizeRecruitingRecurrent WHO Grade III Glioma | WHO Grade III Glioma | WHO Grade II Glioma | Recurrent World Health Organization (WHO) Grade II GliomaUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)CompletedBreast CancerUnited States
-
Daniel M. SpielmanNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedMalignant Central Nervous System Neoplasm | Metastatic Malignant Neoplasm in the Central Nervous SystemUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)Terminated
-
University of CincinnatiActive, not recruitingProstate CancerUnited States